ProMIS Neurosciences, Inc. (PMN) Analysts See $-0.01 EPS

July 14, 2018 - By Lisa Delgado

ProMIS Neurosciences, Inc. (TSE:PMN) Logo

Analysts expect ProMIS Neurosciences, Inc. (TSE:PMN) to report $-0.01 EPS on August, 10.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.01 EPS. After having $-0.01 EPS previously, ProMIS Neurosciences, Inc.’s analysts see 0.00 % EPS growth. It closed at $0.37 lastly. It is up 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

ProMIS Neurosciences Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for treatment of neurodegenerative diseases, primarily Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company has market cap of $90.91 million. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. It currently has negative earnings. The firm applies its thermodynamic, computational discovery platform?ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.